Johnson gets €100m from Europe's IMI to accelerate Ebola vaccine development

January 19, 2015 6:39 AM

7 0

Johnson gets €100m from Europe's IMI to accelerate Ebola vaccine development

Johnson & Johnson (JNJ) through a consortium, which includes research institutions and non-government organizations, is set to receive around €100m ($115m) from Europe's Innovative Medicines Initiative (IMI) to speed up the development of its Ebola vaccine regimen.

The IMI grant will be used to accelerate the development and testing of JNJ's vaccine regimen through a newly formed consortium that includes Janssen, the London School of Hygiene and Tropical Medicine, the University of Oxford and La Centre Muraz.

Read more

To category page

Loading...